Checkpoint Inhibitor Refractory Cancer Market

DelveInsight’s ‘Checkpoint Inhibitor Refractory Cancer—Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Checkpoint Inhibitor Refractory Cancer, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The Checkpoint Inhibitor Refractory Cancer market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Checkpoint Inhibitor Refractory Cancer symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Checkpoint Inhibitor Refractory Cancer symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Checkpoint Inhibitor Refractory Cancer Disease Understanding and Treatment Algorithm

Checkpoint Inhibitor Refractory Cancer Overview

Over the last decade, a major achievement in cancer research has been introducing immune checkpoint inhibitors in treatment. Anti-PD1/PDL1 antibodies are among the most widely prescribed anticancer therapies. Checkpoint inhibitors are now used as single agents or combined with chemotherapies as first or second lines of treatment for about 50 cancer types.

In contrast to old cytotoxic therapies, immune checkpoint inhibitors augment the host immune system to fight cancer. Immune checkpoints are a normal part of the immune system. Their role is to prevent an immune response from being so strong that it destroys healthy cells in the body. However, when the checkpoint and partner proteins bind together in cancer, they send an “off” signal to the T cells preventing the immune system from destroying cancer.


Checkpoint-inhibitor inhibitor Refractory Cancer Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Checkpoint-inhibitor inhibitor Refractory Cancer market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Checkpoint-inhibitor inhibitor Refractory Cancer market report thoroughly understands Checkpoint-inhibitor inhibitor Refractory Cancer symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Checkpoint Inhibitor Refractory Cancer treatment algorithms and treatment guidelines for Checkpoint Inhibitor Refractory Cancer symptoms in the US, Europe, and Japan.


Immune checkpoint inhibitors (ICI) block immune checkpoints. By blocking them, these drugs allow immune cells to respond more strongly to cancer. This prevents the “off” signal from being sent, allowing the T-cells to kill cancer cells. A wide range of cancer types can be treated using checkpoint inhibitors, for example, lung cancer (NSCLC, and SCLC), melanoma, breast cancers (triple-negative, metastatic breast cancer), Hodgkin lymphoma, Urothelial carcinoma, Renal cell cancer (RCC), and several others. Immune checkpoint inhibitors provide an edge over other generally used treatment therapies like chemotherapy, as they possess greater survival time and high potency against cancer cells.


Nevertheless, few side effects are associated with the usage of Immune checkpoint inhibitors, which affect people in different ways. Also, despite being a highly successful therapy choice, there are chances of developing resistance to checkpoint inhibitors because some patients do not respond from the beginning (Primary Resistance; Refractory) or stop responding over time (Acquired Resistance; Relapsed).

Checkpoint Inhibitor Refractory Cancer Epidemiology

The Checkpoint Inhibitor Refractory Cancer symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.


Key Findings

The total incident cases of Checkpoint Inhibitor Refractory Cancer is increasing in 7MM during the study period, i.e., 2018–2030.


The disease epidemiology covered in the report provides historical as well as forecasted Checkpoint Inhibitor Refractory Cancer symptoms epidemiology segmented as the Incidence by tumor type, Checkpoint-inhibitor treated patients and Checkpoint-inhibitor refractory patients. The report includes the incident scenario of Checkpoint Inhibitor Refractory Cancer symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Checkpoint Inhibitor Refractory Cancer Epidemiology

The epidemiology segment also provides the Checkpoint Inhibitor Refractory Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total number of incident cases of Checkpoint Inhibitor Refractory Cancer-associated in 7MM countries was 156,370 in 2020.

Checkpoint Inhibitor Refractory Cancer Drug Chapters

The Checkpoint Inhibitor Refractory Cancer report’s drug chapter segment encloses the detailed analysis of Checkpoint Inhibitor Refractory Cancer early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Checkpoint Inhibitor Refractory Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Checkpoint Inhibitor Refractory Cancer Emerging Drug


MRx0518: 4D pharma plc.

MRx0518 is a single strain Live Biotherapeutic product consisting of a lyophilized formulation of a proprietary strain of bacterium. It is in development for the treatment of cancer. It is delivered as an oral capsule and stimulates the body’s immune system, directing it to produce cytokines and immune cells that are known to attack tumors. It is currently being evaluated in three clinical trials in cancer patients.


Domatinostat (4SC-202): 4SC AG

4SC-202 or Domatinostat is an orally administered small molecule for the treatment of cancer. One of the most promising therapeutic concepts in oncology drug development is the modification of chromatin. The compound inhibits the enzymes histone deacetylase (HDAC) 1, 2, and 3, which are believed to play important roles in regulating aberrant cancer signaling.


Domatinostat induces critical gene signature changes that predict responsivity to PD-(L) 1 checkpoint inhibitors (CI). It synergizes with PD-(L) 1 checkpoint inhibitors in a model representing PD-(L) 1 refractory /non-responding cancers; combining Domatinostat with a checkpoint inhibitor results in a high proportion of durable responses and longer survival rates.

Products detail in the report…

Checkpoint Inhibitor Refractory Cancer Market Outlook

The report’s Checkpoint Inhibitor Refractory Cancer market outlook helps build a detailed comprehension of the historic, current, and forecasted Checkpoint Inhibitor Refractory Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of Checkpoint Inhibitor Refractory Cancer market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.


According to DelveInsight, the Checkpoint Inhibitor Refractory Cancer market in 7MM is expected to grow in the study period 2018–2030.


Although ICI is a successful new approach in cancer therapy, these checkpoint inhibitors may also lead to a loss of immune tolerance of healthy tissue, which results in various side effects, referred to as immune-related adverse events (irAEs). According to few references, up to one-fourth of patients on ipilimumab monotherapy and about the same percentage of patients on combined therapy suffer from severe (grade 3 or 4) enterocolitis. As per Burla (2020), overall, 15–25% of patients on single immunotherapy and about 65% of patients on combined immunotherapy suffer from grade 3 or grade 4 irAEs.


Key Findings

This section includes a glimpse of the Checkpoint Inhibitor Refractory Cancer market in 7MM.


Checkpoint Inhibitor Refractory Cancer market size in the seven major markets was USD 11.5 million in 2020.


The United States Market Outlook

This section provides the total Checkpoint Inhibitor Refractory Cancer market size and market size by therapies in the United States.


The United States accounts for the largest market size of Checkpoint Inhibitor Refractory Cancer compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total Checkpoint Inhibitor Refractory Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Checkpoint Inhibitor Refractory Cancer market Size and market Size by therapies in Japan are also mentioned.

Checkpoint Inhibitor Refractory Cancer Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the Checkpoint Inhibitor Refractory Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and making financial and regulatory decisions.

Checkpoint Inhibitor Refractory Cancer Pipeline Development Activities


The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Checkpoint Inhibitor Refractory Cancer key players involved in developing targeted therapeutics.


Major players include 4D pharma plc, 4SC AG, Ascentage Pharma Group, Eisai Inc., etc.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Checkpoint Inhibitor Refractory Cancer emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Checkpoint Inhibitor Refractory Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Checkpoint Inhibitor Refractory Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Checkpoint Inhibitor Refractory Cancer Market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Checkpoint Inhibitor Refractory Cancer, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the Checkpoint Inhibitor Refractory Cancer epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Checkpoint Inhibitor Refractory Cancer is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Checkpoint Inhibitor Refractory Cancer market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Checkpoint Inhibitor Refractory Cancer market.

Report Highlights

  • In the coming years, the Checkpoint Inhibitor Refractory Cancer market is set to change due to the rising awareness of the disease and the Favorable Environment for New Anti-infective modalities, which would expand the market’s size to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Checkpoint Inhibitor Refractory Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Checkpoint Inhibitor Refractory Cancer. The launch of emerging therapies will significantly impact the Checkpoint Inhibitor Refractory Cancer market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Checkpoint Inhibitor Refractory Cancer Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Checkpoint Inhibitor Refractory Cancer Pipeline Analysis
  • Checkpoint Inhibitor Refractory Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Checkpoint Inhibitor Refractory Cancer Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Checkpoint Inhibitor Refractory Cancer Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Checkpoint Inhibitor Refractory Cancer Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Checkpoint Inhibitor Refractory Cancer Market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Checkpoint Inhibitor Refractory Cancer total market size and market size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the key findings of the market across 7MM, and which country will have the largest Checkpoint Inhibitor Refractory Cancer market Size during the forecast period (2018–2030)?
  • At what CAGR, the Checkpoint Inhibitor Refractory Cancer market is expected to grow in 7MM during the forecast period (2018–2030)?
  • What would be the Checkpoint Inhibitor Refractory Cancer market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Checkpoint Inhibitor Refractory Cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Checkpoint Inhibitor Refractory Cancer?
  • What is the historical Checkpoint Inhibitor Refractory Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Checkpoint Inhibitor Refractory Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Checkpoint Inhibitor Refractory Cancer?
  • Out of all 7MM countries, which country would have the largest incident population of Checkpoint Inhibitor Refractory Cancer during the forecast period (2018–2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Checkpoint Inhibitor Refractory Cancer along with the approved therapy?
  • What are the current treatment guidelines for treating Checkpoint Inhibitor Refractory Cancer in the USA, Europe, and Japan?
  • What are the Checkpoint Inhibitor Refractory Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Checkpoint Inhibitor Refractory Cancer?
  • How many therapies are developed by each company for the treatment of Checkpoint Inhibitor Refractory Cancer?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Checkpoint Inhibitor Refractory Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to Checkpoint Inhibitor Refractory Cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Checkpoint Inhibitor Refractory Cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for Checkpoint Inhibitor Refractory Cancer?
  • What are the global historical and forecasted market of Checkpoint Inhibitor Refractory Cancer?

Reasons to buy

  • The report will help develop business strategies by understanding trends shaping and driving the Checkpoint Inhibitor Refractory Cancer market.
  • To understand the future market competition in the Checkpoint Inhibitor Refractory Cancer market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Checkpoint Inhibitor Refractory Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying upcoming solid players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Checkpoint Inhibitor Refractory Cancer market.
  • To understand the future market competition in the Checkpoint Inhibitor Refractory Cancer market.

1. Key Insights

2. Report Introduction

3. Checkpoint Inhibitor Refractory Cancer Market Overview at a Glance

3.1. Patient Share (%) Distribution of Checkpoint Inhibitor Refractory Cancer in 2018

3.2. Patient Share (%) Distribution of Checkpoint Inhibitor Refractory Cancer in 2030

4. Executive Summary of Checkpoint Inhibitor Refractory Cancer

5. Disease Background and Overview

5.1. Introduction

5.2. Scientific Overview

5.3. Cancer-immunity Cycle

5.4. Checkpoint blockade of the CTLA-4 pathway

5.5. Checkpoint blockade of the PD-1/PD-L1

5.6. Next-generation immune checkpoints for cancer therapy

5.7. Solid tumors

5.7.1. Urothelial Carcinoma

5.7.1.1. Diagnosis

5.7.1.2. Treatment

5.7.1.3. Guidelines for Bladder Cancer

5.7.1.4. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

5.7.2. NSCLC

5.7.2.1. Pathogenesis

5.7.2.2. Diagnosis

5.7.2.3. Treatment

5.7.2.4. Guideline for NSCLC

5.7.2.4.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2021

5.7.2.4.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

5.7.3. Melanoma

5.7.3.1. Pathophysiology

5.7.3.2. Diagnosis

5.7.3.3. Treatment

5.7.4. Renal cell carcinoma

5.7.4.1. Pathophysiology

5.7.4.2. Diagnosis

5.7.4.3. Treatment

5.7.4.4. Guidelines for Renal Cell Carcinoma

5.7.4.4.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2021

5.7.4.4.2. ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

5.7.5. Hodgkin Lymphoma

5.7.5.1. Pathophysiology

5.7.5.2. Diagnosis

5.7.5.3. Treatment

5.7.6. Breast Cancer

5.7.6.1. Pathophysiology

5.7.6.2. Diagnosis

5.7.6.3. Treatment

5.7.7. Cervical Cancer

5.7.7.1. Diagnosis

5.7.7.2. Treatment

5.7.7.3. Guidelines for Cervical Cancer

5.7.7.3.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2021

5.7.7.3.2. ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

5.7.8. Mesothelioma

5.7.8.1. Pathophysiology

5.7.8.2. Diagnosis

5.7.8.3. Treatment

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Incident Population of Checkpoint-inhibitor refractory patients

6.3. Epidemiology of Checkpoint Inhibitors refractory cancer

6.4. The United States

6.4.1. Incidence by tumor type in the United States

6.4.2. Checkpoint-inhibitor treated patients in the United States

6.4.3. Checkpoint-inhibitor refractory patients in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Incidence by tumor type in Germany

6.5.1.2. Checkpoint-inhibitor treated patients in Germany

6.5.1.3. Checkpoint-inhibitor refractory patients in Germany

6.5.2. France

6.5.2.1. Incidence by tumor type in France

6.5.2.2. Checkpoint-inhibitor treated patients in France

6.5.2.3. Checkpoint-inhibitor refractory patients in France

6.5.3. Italy

6.5.3.1. Incidence by tumor type in Italy

6.5.3.2. Checkpoint-inhibitor treated patients in Italy

6.5.3.3. Checkpoint-inhibitor refractory patients in Italy

6.5.4. Spain

6.5.4.1. Incidence by tumor type in Spain

6.5.4.2. Checkpoint-inhibitor treated patients in Spain

6.5.4.3. Checkpoint-inhibitor refractory patients in Spain

6.5.5. United Kingdom

6.5.5.1. Incidence by tumor type in the United Kingdom

6.5.5.2. Checkpoint-inhibitor treated patients in the United Kingdom

6.5.5.3. Checkpoint-inhibitor refractory patients in the United Kingdom

6.6. Japan

6.6.1. Incidence by tumor type in Japan

6.6.2. Checkpoint-inhibitor treated patients in Japan

6.6.3. Checkpoint-inhibitor refractory patients in Japan

7. Organizations contributing towards Checkpoint Inhibitor Refractory Cancer

8. Case Reports

9. Marketed Therapies

10. Checkpoint Inhibitors

10.1. OPDIVO (Nivolumab): Bristol-Myers Squibb

10.1.1. Product Description

10.1.2. Regulatory Milestone

10.1.3. Other Developmental Activities

10.1.4. Pivotal Clinical Trials

10.1.5. Side Effects

10.1.6. Product Profile

10.2. IMFINZI (Durvalumab): AstraZeneca

10.2.1. Product Description

10.2.2. Regulatory Milestones

10.2.3. Recent Developments

10.2.4. Pivotal Trials

10.2.5. Side effects

10.2.6. Product Profile

10.3. Keytruda (Pembrolizumab): Merck

10.3.1. Product Description

10.3.2. Regulatory Milestone

10.3.3. Recent Developments

10.3.4. Pivotal Clinical Trials

10.3.5. Side Effects of Keytruda

10.3.6. Product Profile

10.4. TECENTRIQ (Atezolizumab): Genentech/Hoffmann-La Roche

10.4.1. Product Description

10.4.2. Regulatory milestone

10.4.3. Other Developmental Activities

10.4.4. Recent Developments

10.4.5. Pivotal Clinical Trials

10.4.6. Side Effects of TECENTRIQ

10.4.7. Product Profile

10.5. Libtayo (Cemiplimab): Regeneron Pharmaceuticals

10.5.1. Product Description

10.5.2. Regulatory Milestone

10.5.3. Recent Developments

10.5.4. Other Development Activities

10.5.5. Pivotal Clinical Trials

10.5.6. Side Effects

10.5.7. Product Profile

10.6. Avelumab (Bavencio): Merck KGaA and Pfizer

10.6.1. Product Description

10.6.2. Regulatory Milestone

10.6.3. Recent Development

10.6.4. Other Development Activities

10.6.5. Pivotal Clinical Trials

10.6.6. Side effects

10.6.7. Product Profile

10.7. YERVOY (Ipilimumab): Bristol-Myers Squibb

10.7.1. Product Description

10.7.2. Regulatory Milestone

10.7.3. Other Developmental Activities

10.7.4. Pivotal Clinical Trials

10.7.5. Side Effects

10.7.6. Product Profile

10.8. Erdafitinib: Janssen Research and Development, LLC

10.8.1. Product Description

10.8.2. Other Developmental Activities

10.8.3. Clinical Development

10.8.7. Safety and Efficacy

10.8.8. Product Profile

11. Emerging Therapies

11.1. Key-Cross: Emerging drugs

11.2. MRx0518: 4D pharma plc.

11.2.1. Drug Description

11.2.2. Other development activities

11.2.3. Clinical Development

11.2.3.1. Clinical trial information

11.2.4. Safety and Efficacy

11.2.5. Product Profile

11.3. Domatinostat (4SC-202): 4SC AG

11.3.1. Drug Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.3.1. Clinical trial information

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. TAVO (Tavokinogene telseplasmid): OncoSec Medical

11.4.1. Drug Description

11.4.2. Other development activities

11.4.3. Clinical Development

11.4.3.1. Clinical trial information

11.4.4. Safety and Efficacy

11.4.5. Product Profile

11.5. Sitravatinib (MG-516): Mirati Therapeutics

11.5.1. Drug Description

11.5.2. Other development activities

11.5.3. Clinical Development

11.5.3.1. Clinical trial information

11.5.4. Safety and Efficacy

11.5.5. Product Profile

11.6. APG-115: Ascentage Pharma Group

11.6.1. Drug Description

11.6.2. Other development activities

11.6.3. Clinical Development

11.6.3.1. Clinical trial information

11.6.4. Safety and Efficacy

11.6.5. Product Profile

11.7. ENB003: ENB Therapeutics, Inc.

11.7.1. Drug Description

11.7.2. Other development activities

11.7.3. Clinical Development

11.7.3.1. Clinical trial information

11.7.4. Safety and Efficacy

11.7.5. Product Profile

11.8. Cavrotolimod (AST-008): Exicure, Inc.

11.8.1. Drug Description

11.8.2. Other development activities

11.8.3. Clinical Development

11.7.3.1. Clinical trial information

11.8.4. Safety and Efficacy

11.8.5. Product Profile

11.9. EDP1503: Evelo Biosciences, Inc./Merck Sharp & Dohme Corp.

11.9.1. Product Description

11.9.2. Other Development Activities

11.9.3. Clinical Development

11.9.3.1. Clinical trial information

11.9.4. Safety and Efficacy

11.9.5. Product Profile

11.10. Lenvima (Lenvatinib Mesylate): Eisai

11.10.1. Drug Description

11.10.2. Other development activities

11.10.3. Clinical Development

11.10.3.1. Clinical trial information

11.10.4. Safety and Efficacy

11.10.5. Product Profile

11.11. KRT-232: Kartos Therapeutics

11.11.1. Drug Description

11.11.2. Clinical Development

11.11.2.1. Clinical trial information

11.11.3. Safety and Efficacy

11.11.4. Product Profile

11.12. Cabozantinib: Exelixis

11.12.1. Drug Description

11.12.2. Other Developmental Activities

11.12.3. Clinical Development

11.12.3.1. Clinical trial information

11.12.4. Product Profile

11.13. Anktiva (N-803): ImmunityBio

11.13.1. Drug Description

11.13.2. Other development activities

11.13.3. Clinical Development

11.13.3.1. Clinical trial information

11.13.4. Product Profile

12. Other Promising Therapies

13. Checkpoint Inhibitor Refractory Cancer: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of Checkpoint Inhibitor Refractory Cancer in 7MM

13.3. Market Outlook

13.4. United States Market Size

13.4.1. Total Market Size of Checkpoint Inhibitor Refractory Cancer in the United States

13.4.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in the United States

13.5. EU-5 Market Size

13.5.1. Germany

13.5.1.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in Germany

13.5.1.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in Germany

13.5.2. France

13.5.2.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in France

13.5.2.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in France

13.5.3. Italy

13.5.3.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in Italy

13.5.3.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in Italy

13.5.4. Spain

13.5.4.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in Spain

13.5.4.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in Spain

13.5.5. United Kingdom

13.5.5.1. Total market size of Checkpoint Inhibitor Refractory Cancer in the United Kingdom

13.5.5.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in the United Kingdom

13.6. Japan

13.6.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in Japan

13.6.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in Japan

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Checkpoint Inhibitor Refractory Cancer, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Recommendations for treatment-naive advanced or metastatic UC

Table 3: Summary of recommendations

Table 4: Summary of recommendations for immune and targeted therapy

Table 5: Systemic Therapy Regimens for Neoadjuvant and Adjuvant Therapy

Table 6: Concurrent Chemoradiation Regimens

Table 7: Targeted therapy or Immunotherapy for Advanced or Metastatic Disease

Table 8: Principles of Systemic Therapy

Table 9: Principles of systemic therapy for relapse or stage IV disease

Table 10: Systemic Therapy for Non-clear Cell Histology

Table 11: Systemic Therapy for cervical cancer

Table 12: Total Incident Population of Checkpoint-inhibitor refractory patients in 7MM(2018–2030)

Table 13: Incidence by tumor type in the United States (2018–2030)

Table 14: Checkpoint-inhibitor treated patients in the United States (2018–2030)

Table 15: Checkpoint-inhibitor refractory patients in the United States (2018–2030)

Table 16: Incidence by tumor type in Germany (2018–2030)

Table 17: Checkpoint-inhibitor treated patients in Germany (2018–2030)

Table 18: Checkpoint-inhibitor refractory patients in Germany (2018–2030)

Table 19: Incidence by tumor type in France (2018–2030)

Table 20: Checkpoint-inhibitor treated patients in France (2018–2030)

Table 21: Checkpoint-inhibitor refractory patients in France (2018–2030)

Table 22: Incidence by tumor type in Italy (2018–2030)

Table 23: Checkpoint-inhibitor treated patients in Italy (2018–2030)

Table 24: Checkpoint-inhibitor refractory patients in Italy (2018–2030)

Table 25: Incidence by tumor type in Spain (2018–2030)

Table 26: Checkpoint-inhibitor treated patients in Spain (2018–2030)

Table 27: Checkpoint-inhibitor refractory patients in Spain (2018–2030)

Table 28: Incidence by tumor type in the United Kingdom (2018–2030)

Table 29: Checkpoint-inhibitor treated patients in the United Kingdom (2018–2030)

Table 30: Checkpoint-inhibitor refractory patients in the United Kingdom (2018–2030)

Table 31: Incidence by tumor type in Japan (2018–2030)

Table 32: Checkpoint-inhibitor treated patients in Japan (2018–2030)

Table 33: Checkpoint-inhibitor refractory patients in Japan (2018–2030)

Table 34: Organizations contributing toward cancer

Table 36: Pivotal Clinical Trials for OPDIVO

Table 37: Pivotal Clinical Trials for IMFINZI

Table 38: Pivotal Clinical Trials

Table 39: Pivotal Clinical Trials

Table 40: Pivotal clinical trials for Libtayo

Table 41: Pivotal clinical trials for Bavencio

Table 42: Pivotal Clinical Trials

Table 35: Erdafitinib, Clinical Trial Description, 2021

Table 44: MRx0518, Clinical Trial Description, 2021

Table 45: 4SC-202, Clinical Trial Description, 2021

Table 46: Tavokinogene telseplasmid, Clinical Trial Description, 2021

Table 47: MG-516, Clinical Trial Description, 2021

Table 48: APG-115, Clinical Trial Description, 2021

Table 49: ENB003, Clinical Trial Description, 2021

Table 50: AST-008, Clinical Trial Description, 2021

Table 51: EDP1503, Clinical Trial Description, 2021

Table 52: Lenvatinib Mesylate, Clinical Trial Description, 2021

Table 53: KRT-232, Clinical Trial Description, 2021

Table 54: Cabozantinib, Clinical Trial Description, 2021

Table 55: Anktiva, Clinical Trial Description, 2021

Table 59: Seven Major Market Size of Checkpoint Inhibitor Refractory Cancer in USD Million (2018–2030)

Table 60: United States Market Size of Checkpoint Inhibitor Refractory Cancer in USD Million (2018–2030)

Table 61: United States Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million (2018–2030)

Table 62: Germany Market Size of Checkpoint Inhibitor Refractory Cancer in USD Million (2018–2030)

Table 63: Germany Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million (2018–2030)

Table 64: France Market Size of Checkpoint Inhibitor Refractory Cancer in USD Million (2018–2030)

Table 65: France Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million (2018–2030)

Table 66: Italy Market Size of Checkpoint Inhibitor Refractory Cancer in USD Million (2018–2030)

Table 67: Italy Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million (2018–2030)

Table 68: Spain Market Size of Checkpoint Inhibitor Refractory Cancer in USD Million (2018–2030)

Table 69: Spain Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million (2018–2030)

Table 70: United Kingdom Market Size of Checkpoint Inhibitor Refractory Cancer in USD Million (2018–2030)

Table 71: United Kingdom Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million (2018–2030)

Table 72: Japan Market Size of Checkpoint Inhibitor Refractory Cancer in USD Million (2018–2030)

Table 73: Japan Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Cancer Immunity Cycle

Figure 2: CTLA-4 Immune checkpoint

Figure 3: PD-1 Immune checkpoint

Figure 4: Total Incident Population of Checkpoint-inhibitor refractory patients in 7MM in 000’s (2018–2030)

Figure 5: Incidence by tumor type in the United States in 000s (2018–2030)

Figure 6: Checkpoint-inhibitor treated patients in the United States in 000s (2018–2030)

Figure 7: Checkpoint-inhibitor refractory patients in the United States in 000s (2018–2030)

Figure 8: Incidence by tumor type in Germany in 000s (2018–2030)

Figure 9: Checkpoint-inhibitor treated patients in Germany in 000s (2018–2030)

Figure 10: Checkpoint-inhibitor refractory patients in Germany in 000s (2018–2030)

Figure 11: Incidence by tumor type in France in 000s (2018–2030)

Figure 12: Checkpoint-inhibitor treated patients in France in 000s (2018–2030)

Figure 13: Checkpoint-inhibitor refractory patients in France in 000s (2018–2030)

Figure 14: Incidence by tumor type in Italy in 000s (2018–2030)

Figure 15: Checkpoint-inhibitor treated patients in Italy in 000s (2018–2030)

Figure 16: Checkpoint-inhibitor refractory patients in Italy in 000s (2018–2030)

Figure 17: Checkpoint-inhibitor treated patients in Spain in 000s (2018–2030)

Figure 18: Checkpoint-inhibitor refractory patients in Spain in 000s (2018–2030)

Figure 19: Incidence by tumor type in the United Kingdom in 000s (2018–2030)

Figure 20: Checkpoint-inhibitor treated patients in the United Kingdom in 000s (2018–2030)

Figure 21: Checkpoint-inhibitor refractory patients in the United Kingdom in 000s (2018–2030)

Figure 22: Incidence by tumor type in Japan in 000s (2018–2030)

Figure 23: Checkpoint-inhibitor treated patients in Japan in 000s (2018–2030)

Figure 24: 7 Major Market Size of Checkpoint Inhibitor Refractory Cancer in USD Million (2018–2030)

Figure 25: Market Size of Checkpoint Inhibitor Refractory Cancer in the United States, USD Million (2018–2030)

Figure 26: The United States Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million (2018–2030)

Figure 27: Market Size of Checkpoint Inhibitor Refractory Cancer in Germany, USD Million (2018–2030)

Figure 28: Germany Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million

Figure 29: Market Size of Checkpoint Inhibitor Refractory Cancer in France, USD Million (2018–2030)

Figure 30: France Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million (2018–2030)

Figure 31: Market Size of Checkpoint Inhibitor Refractory Cancer in Italy, USD Million (2018–2030)

Figure 32: Italy Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million

Figure 33: Market Size of Checkpoint Inhibitor Refractory Cancer in Spain, USD Million (2018–2030)

Figure 34: Spain Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million

Figure 35: Market Size of Checkpoint Inhibitor Refractory Cancer in the United Kingdom, USD Million (2018–2030)

Figure 36: The United Kingdom Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million

Figure 37: Market Size of Checkpoint Inhibitor Refractory Cancer in Japan, USD Million (2018–2030)

Figure 38: Japan Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in USD Million

• Bristol-Myers Squibb

• AstraZeneca

• Merck

• Genentech/Hoffmann-La Roche

• Regeneron Pharmaceuticals

• Merck KGaA and Pfizer

• Bristol-Myers Squibb

• Janssen Research and Development, LLC

• 4D pharma plc.

• 4SC AG

• OncoSec Medical

• Mirati Therapeutics

• Ascentage Pharma Group

• ENB Therapeutics, Inc.

• Exicure, Inc.

• Evelo Biosciences, Inc./Merck Sharp & Dohme Corp.

• Eisai

• Kartos Therapeutics

• Exelixis

• ImmunityBio

  • Tags:
  • Checkpoint Inhibitor Refractory Can...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...
  • Checkpoint Inhibitor Refractory Ca...

Forward to Friend

Need A Quote